Merck

Merck & Co. is already a well-established top worldwide player in the pharmaceutical business, with about 60 billion US dollars in revenue. Merck & Co., Inc.'s origins can be traced back to the 17th century: Jacob Friedrich Merck founded the company in 1668 as a bought pharmacy store in Darmstadt, Germany. In 1891, a subsidiary called Merck & Co. was established in the United States. Merck & Co. has been an independent U.S. American firm since 1917 when it was commandeered by the US during World War I.

The company's offerings include vaccines, cancer treatments, and animal health items. Merck & Co. has one of the most approved pharmaceuticals as a firm, and it invests much in research and development. Diabetes, a chronic condition plagues society, is the goal of two of the company's most important medicines. Januvia (sitagliptin) is one of the most popular diabetes medications since it does not promote weight gain. In 2022, the medicine generated approximately 2.8 billion US dollars in sales. However, Merck's top product is the blockbuster cancer drug Keytruda.

Merck & Co. is a global corporation that generates more than half of its income outside of the United States. Merck & Co., one of the world's major pharmaceutical firms, with over 69,000 employees in 2022, scattered across 100 countries. In the same year, the company's total assets amounted to approximately 109 billion US dollars.

Merck is investing €250 million ($275.5 million) in a biotechnology development facility in Corsier-sur-Vevey, Switzerland. The facility will concentrate on the development of biotech medications as well as clinical study production. It is being built as a bridge between research and manufacturing of newly found drugs. In January 2020, the corporation performed a groundbreaking ceremony for the biotech development center. The facility's structural work was finished with a topping-out ceremony in July 2021. The next stage of its development will entail interior design and equipment installation, with the center set to open in 2023. The site is close to the company's current commercial biotech manufacturing facility in Corsier-sur-Vevey. It will consist of a structure with a total size of roughly 15,700m2 (168,993m2), with operations supported by around 250 personnel who are currently located in various places. The multidisciplinary team will aim to accelerate the availability of breakthrough biotech treatments for clinical trials.

Founded: 1891

Headquarters: Rahway, New Jersey, U.S.

Website: https://www.merck.com/